LTI-2355 / Rein Therapeutics - LARVOL DELTA

Evaluating Alveolar Regenerative Properties of Caveolin Scaffolding Peptides (CSD) in Three Dimensional (3D) Alveolospheres From IPF and Normal Donor Lung Samples (ATS 2025) - "LTI-03 and LTI-2355 increased the outgrowth of IPF alveolospheres in 3D tissue culture indicating that LTI CSD peptides exert a putative pro-regenerative effect on IPF AT2 cells. In contrast, nintedanib exhibited inhibitory effects on the outgrowth of normal donor alveolospheres . Ethical approval: Institutional Review Boards both at Cedars-Sinai Medical Center and Aileron Therapeutics approved all experiments with human tissue."

Idiopathic Pulmonary Fibrosis • Immunology

Evaluating Alveolar Regenerative Properties of Caveolin Scaffolding Peptides (CSD) in Three Dimensional (3D) Alveolospheres from IPF and Normal Donor Lung Samples (PRNewswire) - "Rein Therapeutics...announced that the Company and its collaborators presented...posters supporting the potential therapeutic effectiveness of LTI-03 in idiopathic pulmonary fibrosis (IPF) at the American Thoracic Society (ATS) 2025 International Conference....Cav1 scaffolding domain peptides LTI-03 or LTI-2355 sustained AEC2s in IPF lung organoids or alveolospheres, further supporting LTI-03's ability to promote alveolar epithelial cell survival. At the 10.0 μM dose, both LTI-03 and LTI-2355 increased the size of IPF alveolospheres compared to placebo at Day 28. Both LTI-03 and LTI-2355 appeared to protect normal lung alveolopheres, while nintedanib demonstrated significant growth-inhibiting or toxic effects on normal donor lung organoids at Day 28."

Preclinical • Idiopathic Pulmonary Fibrosis

Caveolin Scaffolding Domain (CSD) Peptide LTI-2355 Modulates the Phagocytic and Synthetic Activity of Lung-Derived Myeloid Cells in Idiopathic Pulmonary Fibrosis (IPF) and Post-Acute Sequelae of COVID Fibrosis (PASC-F). (PubMed, Biomedicines) - "LTI-2355 treatment of IPF myeloid cells resulted in significantly reduced sCD163, IFN-α2, IFN-γ, IL-2, IL-10, IL-12p40, and MMP-1 in the cell supernatant. This study highlights an additional mechanism of action of the CSD peptide in the treatment of IPF and progressive fibrotic lung disease."

Journal • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Inflammation • Novel Coronavirus Disease • Pulmonary Disease • Respiratory Diseases • IFNA1 • IFNG • IL10 • IL2 • MMP1 • MRC1 • PTPRC

Rein Therapeutics Announces a Publication in Biomedicines on the Immunomodulatory and Anti-fibrotic Properties of a Caveolin-1-Related Peptide in IPF and PASC-F (PRNewswire) - P=NA | N=NA | "Rein Therapeutics...today announced a publication highlighting the therapeutic potential of Caveolin-1-related peptide LTI-2355 in Idiopathic Pulmonary Fibrosis (IPF) and Post-Acute Sequelae of COVID Fibrosis (PASC-F) in the peer-reviewed journal, Biomedicines....In the present study, LTI-2355 improved the phagocytic (i.e., anti-infective) activity of both IPF and PASC-F myeloid cells compared with control peptide-treated cells, and this improvement coincided with decreased pro-inflammatory and pro-fibrotic synthetic activity of the diseased cells....These results indicate that LTI-2355 effectively reduces both inflammatory and fibrotic properties of myeloid cells, which contribute to the progression and exacerbation of lung fibrosis."

Clinical data • Idiopathic Pulmonary Fibrosis